About

Important information

• Pending Government Action:

  Government Action: BBB reports on known government actions involving business’ marketplace conduct:

  FTC Takes Action Against Telemedicine Firm NextMed Over Charges It Used Misleading Prices, Fake Reviews, and Deceptive Weight Loss Claims to Sell GLP-1 Weight-Loss Programs
  

  The following describes a pending government action that has been formally brought by a government agency but has not yet been resolved. We are providing a summary of the governments allegations, which have not yet been proven.

  
  

  On July 14, 2025, the operators of telemedicine company Southern Health Solutions, Inc., doing business as Next Medical and NextMed, have agreed to settle the Federal Trade Commission’s (FTC) charges that they used deceptive cost and weight loss claims, as well as fake reviews and testimonials to lure consumers into buying their weight-loss membership programs that had hidden terms and conditions.
  
  
  
  In its complaint, the FTC alleges that New York-based NextMed, its founders Robert Epstein, and CEO Frank Leonardo III sold telehealth weight-loss programs providing access to medical providers who could prescribe popular glucagon-like peptide 1 agonist (GLP-1) weight-loss drugs, such as Wegovy and Ozempic, that were the subject of skyrocketing interest when NextMed began offering its weight-loss programs in early 2022. NextMed sold its membership programs at an advertised monthly price, typically at $138 or $188, without adequately disclosing that the price did not include the cost of the actual GLP-1 drug, the cost of the lab work required to determine eligibility for such drugs, or the cost of the consultation with a medical provider that was necessary to obtain a prescription.
  
  
  
  The complaint also alleges that NextMed failed to adequately disclose that its membership programs had a required one-year commitment with early termination fees, and that many customers who called to cancel or request refunds faced significant delays in resolving their complaints due to NextMed’s insufficient customer service staffing and capacity.
  
  
  
  The FTC also alleged that the company suppressed negative reviews on Trustpilot by selectively challenging critical reviews, offering Amazon gift cards to consumers to remove or change negative reviews, and by conditioning refunds on consumers’ agreement to remove negative reviews. In addition, the complaint alleges that the company generated fake positive reviews that were posted on Trustpilot and used testimonials and before-and-after photos from people who were not NextMed clients and had not used GLP-1 drugs for weight loss.  
  
  
  
  In addition to requiring NextMed and its principals to pay $150,000, which is expected to be used to provide refunds to consumers, the proposed consent order:
  
  
  
  -prohibits them from misrepresenting the cost of telehealth services, including what is included in that cost, the timing or manner of billing or any charge, that a consumer authorized a transaction or is obligated to pay a charge, or material information relating to refund and cancellation policies;
  
  -requires competent and reliable evidence to support claims about the average or typical results users will achieve;
  
  -prohibits misrepresentations that reviews are truthful or from real consumers, and requires disclosure of any unexpected material connection with endorsers or reviewers;
  
  -prohibits manipulation of reviews, including selectively soliciting reviews from consumers more likely to provide positive reviews, offering payments or incentives to consumers to remove or edit negative reviews, and reporting or disputing negative reviews as false or suspicious without a reasonable basis for doing so;
  
  -requires them to obtain informed consent before billing consumers and authorization to use any electronic fund transfer; and
  
  -requires them to clearly disclose important terms relating to refunds or cancellations before consumers are asked to pay, provide a simple way for consumers to request cancellations or refunds, and to promptly honor any cancellation or refund requests that comply with policies that were in effect at the time of purchase.
  
  
  
  The FTC will publish a description of the consent agreement package in the Federal Register. The agreement will be subject to public comment for 30 days after publication in the Federal Register, after which the Commission will decide whether to make the proposed consent order final. Instructions for filing comments will appear in the published notice. Once processed, comments will be posted on Regulations.gov. Comments must be received on or before August 18, 2025.

  Click here for details